NCT03762369View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

PHASE3UnknownINTERVENTIONAL
Enrollment

384

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

February 28, 2022

Study Completion Date

May 30, 2022

Conditions
Primary Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

CKD-351

twice a day

DRUG

Latanoprost

once a day

DRUG

D930

three times a day

DRUG

Placebo of CKD-351

once a day

DRUG

Placebo of CKD-351

twice a day

DRUG

Placebo of D930

three times a day

Trial Locations (1)

Unknown

Seoul National University Hosipital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT03762369 - A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 | Biotech Hunter | Biotech Hunter